Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy

Diabetes Care

Volumn 19, Issue 2, 1996, Pages 151-156

  Iwamoto, Yasuhiko ^a   Kosaka, Kinori ^b   Kuzuya, Takeshi ^c,e   Akanuma, Yasuo ^b   Shigeta, Yukio ^d   Kaneko, Toshio ^c,e  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e YAMAGUCHI ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTATE DEHYDROGENASE; LIPID; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0030033508     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.2.151     Document Type: Article

References (17)

1. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus, a balanced overview. Diabetologia 35: 389-397, 1992
2. Taylor SI, Accili D, Imai Y: Insuhn resistance or insulin deficiency: which is the primary cause of NlDDM? Diabetes 43: 735-740, 1994
3. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H: Studies on hindered phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation J Med Chem 32:421-428, 1989
4. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
5. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich A: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
6. Honkoshi H, Fujiwara T, Yoshioka T, Yoshioka S, Wada M, Fukarru M: Pharmacological characteristic of new antidiabetic agent CS-045 in diabetic animals. Front Diabetic Res 8:320-324, 1990
7. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Haring H: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43:447-453, 1994
8. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, Horikoshi H, Serizawa N: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135:2279-2282, 1994
9. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes, Care 14:1083-1086, 1991
10. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-154, 1991
11. Shigeta Y, Kobayashi M, Kosaka K, Shimizu N, Kaneko T, Kuzuya T, Akanuma Y: Clinical evaluation of a new oral hypoglycemic agent CS-045 in uncontrolled non-insulin dependent diabetic patients Diabetes 41 (Suppl. 1):76A, 1992
12. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15:193-203, 1992
13. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
14. Lee MK, Miles PDG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM: Metabolic effect of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439, 1994
15. Katayama S, Abe M, Kashiwabara H, Kosegawa I, Ishii J Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. Hypertension 23:1071-1074, 1994
16. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
17. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995